COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01404117
Recruitment Status : Withdrawn (Study is being redesigned)
First Posted : July 27, 2011
Last Update Posted : August 27, 2013
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability and efficacy of two daily doses of oral laquinimod (0.6mg or 1.2mg) in adjunct to glatiramer acetate (GA) or interferon-beta (IFN-B) in relapsing remitting multiple sclerosis (RRMS) subjects

Condition or disease Intervention/treatment Phase
Relapsing Multiple Sclerosis Drug: Laquinimod 0.6 Drug: Laquinimod 1.2 Other: Glatiramer Acetate or interferon-beta+ Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : March 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Laquinimod 0.6
GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
Drug: Laquinimod 0.6
Laquinimod 0.6 capsule

Experimental: Laquinimod 1.2
GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
Drug: Laquinimod 1.2

Experimental: GA or IFN + Placebo
GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
Other: Glatiramer Acetate or interferon-beta+ Placebo
GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo

Primary Outcome Measures :
  1. Safety and efficacy [ Time Frame: 10 months ]
    To assess the safety, tolerability and efficacy of laquinimod in RRMS

Secondary Outcome Measures :
  1. Tolerability [ Time Frame: 10 months ]
    To assess the safety, tolerability and efficacy of laquinimod in RRMS as compared to placebo, subjects treated with GA or an IFN-B preparation (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must have a documented MS diagnosis as defined by the Revised McDonald criteria [Ann Neurol 2011: 69:292-302], with a relapsing-remitting disease course.
  2. Subjects must be ambulatory with an EDSS score of 1-5.5 (inclusive) at the baseline visit.
  3. Subjects must be relapse-free and in a stable neurological condition and free of corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or oral] 30 days prior to screening (month -1).
  4. Subjects must be treated with either Copaxone® or an IFN-B preparation (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®), at a stable dose for at least 6 months prior to the screening visit (switching between IFN-B preparations during the 6 months prior to screening is allowed; switching between any IFN-B preparation and GA, or vice versa, is exclusionary).
  5. Subjects must have had experienced at least one documented relapse in the 36 weeks prior to randomization, with an incomplete recovery of the neurological functions as compared to pre-relapse status.
  6. Subjects must be between 18 and 55 years of age, inclusive.
  7. Women of child-bearing potential must practice an acceptable method of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive or double-barrier method (condom or diaphragm with spermicide)].
  8. Subjects must be able to sign and date a written informed consent prior to entering the study.
  9. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria:

  1. An onset of a relapse between Month -1 (Screening) and 0 (Baseline), unstable neurological condition or any treatment with corticosteroids [intravenous (IV), intramuscular (IM) and/or oral] or Adrenocorticotropic hormone.
  2. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to Screening.
  3. Use of immunosuppressive including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.
  4. Previous use of either of the following: natalizumab (Tysabri®), cladribine, laquinimod, and fingolimod (Gilenya®).
  5. Previous treatment with intravenous immunoglobulin (IVIG) within 2 months prior to screening visit.
  6. Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.
  7. Previous total body irradiation or total lymphoid irradiation.
  8. Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
  9. Use of moderate/strong inhibitors of cytochrome P450 CYP3A4 within 2 weeks prior to the screening visit.
  10. Use of inducers of CYP3A4 within 2 weeks prior to the screening visit.
  11. Use of amiodarone within 2 years prior to screening visit.
  12. Pregnancy or breastfeeding.
  13. A ≥3xULN serum elevation of either alanine transaminase (ALT) or aspartate transaminase (AST) at screening.
  14. Serum direct bilirubin which is ≥2x upper limit of normal (ULN) at screening.
  15. Subjects with a potentially clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include (but are not limited to):

    • A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.
    • A gastrointestinal disorder that may affect the absorption of study medication.
    • Renal or metabolic diseases
    • Any form of acute or chronic liver disease
    • Known human immunodeficiency virus (HIV) positive status
    • A history of drug and/or alcohol abuse
    • An unstable psychiatric disorder.
    • A known history of tuberculosis.
    • Unstable psychiatric disorder
    • Any malignancies, excluding basal cell carcinoma (BCC), in the last 5 years.
  16. A glomerular filtration rate less than 60 ml/min at screening visit.
  17. A known history of sensitivity to gadolinium (Gd).
  18. Inability to successfully undergo MRI scanning.
  19. Previous endovascular treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI).
  20. Known drug hypersensitivity that would preclude administration of laquinimod, such as hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01404117

Sponsors and Collaborators
Teva Pharmaceutical Industries
Layout table for investigator information
Principal Investigator: Ralf Gold, MD
Layout table for additonal information
Responsible Party: Teva Pharmaceutical Industries Identifier: NCT01404117    
Other Study ID Numbers: LAQ-MS-201
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: August 27, 2013
Last Verified: August 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Glatiramer Acetate
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic
Immunosuppressive Agents
Antirheumatic Agents